National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved September 1997

Specific Treatments:


General Information

Neurex Corporation received marketing clearance from the U.S. Food and Drug Administration (FDA) for Corlopam. Corlopam is an intervenous treatment for severe high blood pressure. Corlopam is administered in the hospital over a six-hour to 48-hour period to relieve severe hypertensive spikes.